Dexlansoprazole — sold as Dexilant, and previously as Kapidex — is a proton pump inhibitor, the same class as omeprazole, lansoprazole and esomeprazole. What makes it different is the capsule, not the drug: it uses a dual delayed-release design that dispenses the medication in two separate waves rather than one, giving a longer stretch of acid control from a single dose.
In practical terms that means two things. It’s the one PPI you can take without planning your day around a meal, and it keeps stomach pH above 4 for noticeably longer than the drug it’s derived from. Whether that translates into you feeling better depends a great deal on what kind of reflux you have — and for silent reflux in particular, the honest answer is that the theory is more convincing than the evidence.
Here’s what the formulation actually does, what it’s approved for, how to take it, what it costs now that a generic exists, and where I think it genuinely earns consideration over a cheaper PPI.
Key Takeaways
- Dexlansoprazole (Dexilant) is a proton pump inhibitor — specifically the R-enantiomer of lansoprazole, delivered in a dual delayed-release capsule.
- The capsule contains two types of granules that dissolve at different points in the gut, producing two plasma peaks: one at 1–2 hours and a second at 4–5 hours.
- That design keeps gastric pH above 4 for around 17 hours a day at 60 mg, compared with about 14 hours for lansoprazole 30 mg.
- It’s the only PPI licensed to be taken without regard to food — no 30-minutes-before-breakfast rule.
- Approved doses: 60 mg daily for up to 8 weeks to heal erosive esophagitis, 30 mg daily for maintenance, and 30 mg daily for 4 weeks in non-erosive GERD.
- Side effects are typical for the class and uncommon: diarrhea (4.8%), abdominal pain (4.0%) and nausea (2.9%) top the list.
- A generic is now available, but cash prices still run far above generic omeprazole or pantoprazole.
- There is no published trial showing it works for LPR — the one placebo-controlled LPR study was terminated after enrolling 11 patients.
Is Dexilant a Proton Pump Inhibitor?
Yes. Dexilant is dexlansoprazole, which is the R-enantiomer of lansoprazole — the mirror-image half of the older drug that does most of the work and is cleared from the body more slowly. It shuts down the stomach’s proton pumps by exactly the same mechanism as every other PPI, so everything that applies to the class applies here: it takes a few days of dosing to reach full effect, it doesn’t neutralize acid already present, and stopping it abruptly can cause rebound.
The reason it gets talked about as something special is the delivery system, so that’s worth understanding properly before deciding whether it’s worth paying for.
What Dual Delayed Release Actually Does
A standard PPI capsule releases its contents in one go once it clears the stomach. You get a single plasma peak, the pumps that are active at that moment get blocked, and by the evening the drug is long gone even though new pumps are still being made. That single-shot pharmacology is the reason so many people end up taking a PPI twice a day.
Dexlansoprazole splits the dose. The capsule holds two kinds of enteric-coated granules that dissolve at different pH levels, so the first batch releases in the upper small intestine and the second further along. The result is a plasma profile with two distinct peaks — the first at one to two hours after the dose, the second at four to five hours [DailyMed, DEXILANT Prescribing Information, 2024].
That second wave is the whole point. At 60 mg, dexlansoprazole holds intragastric pH above 4 for roughly 17 hours out of 24, about 71% of the day, compared with around 14 hours (60%) for lansoprazole 30 mg [Olsen and Hitzeman, Clinical Medicine Insights: Therapeutics, 2009]. Three extra hours of coverage from one capsule is a real pharmacological difference — the question is always whether it changes outcomes, and that varies by condition.
What It’s Approved For, and at What Dose
The licensed uses are narrower than people assume. According to the prescribing information, dexlansoprazole is approved for:
- Healing erosive esophagitis — 60 mg once daily for up to 8 weeks, in patients aged 12 and over.
- Maintaining healed erosive esophagitis and relieving heartburn — 30 mg once daily, studied for up to 6 months in adults.
- Symptomatic non-erosive GERD — 30 mg once daily for 4 weeks.
On healing rates it performs about as you’d expect for a well-dosed PPI: trials put dexlansoprazole at 92–95% healing of erosive esophagitis at eight weeks against 86–92% for lansoprazole, with the advantage clearest in moderate-to-severe disease. In non-erosive GERD, a four-week trial of 947 patients found 54.9% of people on 30 mg achieved 24-hour heartburn-free days against 18.5% on placebo [Olsen and Hitzeman, Clinical Medicine Insights: Therapeutics, 2009].
Note what isn’t on that list: throat symptoms, cough, hoarseness, globus. No PPI is licensed for those, which is worth remembering whenever a reflux drug is prescribed for a throat problem.
When to Take Dexilant — Morning or Night?
This is the question I get asked most about this drug, and it has a better answer than it does for other PPIs.
With omeprazole and its relatives, timing is genuinely fiddly: they need to be taken 30–60 minutes before a meal, because the meal is what activates the pumps the drug then blocks. Get that wrong and you lose a meaningful chunk of the effect — which is why I wrote a whole guide on the best time of day to take omeprazole.
Dexlansoprazole is different. The label states plainly that it can be taken without regard to food, because the staggered release means there’s always drug arriving at some point after a meal rather than one narrow window to hit [DailyMed, DEXILANT Prescribing Information, 2024]. Swallow the capsule whole, don’t chew it, and take it at whatever time you’ll actually remember.
My practical view: if your symptoms are worst overnight, an evening dose is reasonable, since the second release wave then lands during the hours you’re lying down. If they’re worst during the day, take it in the morning. The bigger win with this drug is not having to schedule your breakfast around a tablet — adherence is where most PPI courses fall down, and a drug you take correctly at a mediocre time beats one you take incorrectly at the ideal time.
Dexlansoprazole for LPR and Silent Reflux
This is the part that interests me most, and where I have to be careful to separate a good idea from a proven one.
The logic runs like this. In LPR, the damage is done by small amounts of refluxate — often weakly acidic, carrying pepsin — reaching the throat, where there’s no protective mechanism worth speaking of. Because even brief acidic episodes can reactivate pepsin already deposited in laryngeal tissue, the conventional approach has been twice-daily PPI dosing to minimize the gaps in coverage. A capsule that extends coverage by several hours on its own is, on paper, a neat solution to exactly that problem.
Then the evidence. There is no published randomized trial of dexlansoprazole for LPR. A placebo-controlled study at Indiana University set out to test precisely this idea — 60 mg once daily in patients with pH-probe-confirmed LPR and a reflux symptom index of 14 or more — and was terminated after enrolling 11 participants. So the LPR-specific question has never actually been answered.
What we do have is indirect. A 2024 randomized trial in 132 LPR patients compared twice-daily with once-daily dosing of a long-acting PPI and found no significant difference in symptom response at 16 weeks — 32.0% versus 37.3% — with both regimens improving symptom scores and laryngeal findings [Ji et al., Journal of Neurogastroenterology and Motility, 2024]. That cuts two ways: it supports the idea that one well-designed daily dose can do the job of two, and it’s a reminder that the response rates for PPIs in LPR are modest whichever way you dose them.
My honest position is the one I take on this whole class of drug: if acid suppression is going to help your throat symptoms, it generally does so within eight to twelve weeks, and a longer-acting formulation is a sensible thing to try before concluding PPIs don’t work for you. But if you’ve already had a fair trial and nothing changed, switching to a more expensive PPI is unlikely to be the answer — the reasons PPIs often don’t work for LPR have more to do with non-acid reflux and pepsin than with how many hours the pH stays above 4. I go through the alternatives in the best medications for LPR and what to do when reflux medication isn’t working.
Diet does the part the drug can’t. Acid suppression changes the pH of what refluxes; it doesn’t reduce how often reflux happens, and it doesn’t remove pepsin from the equation. That’s the gap the Wipeout Diet Plan was built to close — I designed it around silent reflux, the throat-based form that responds worst to medication, though it works just as well for classic GERD because the underlying mechanics are the same.
Dexilant Side Effects
For a drug taken daily, the short-term side effect profile is reassuringly boring. In the clinical trials behind the label, the reactions reported in at least 2% of adults were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory infection (1.9%), vomiting (1.6%) and flatulence (1.6%) [DailyMed, DEXILANT Prescribing Information, 2024]. Most people notice nothing at all.
The considerations that matter are the class-wide ones that come with long-term acid suppression rather than anything specific to this molecule: reduced absorption of B12, iron, magnesium and other nutrients, which I cover in what nutrients PPIs deplete, along with the modest signals around bone density and enteric infections. None of that is a reason to avoid a course of treatment; all of it is a reason not to stay on one indefinitely by default. The full picture is in my guide to omeprazole side effects, which applies to the class.
One genuinely useful detail: dexlansoprazole is metabolized by CYP2C19, and people who are poor metabolizers of that enzyme can end up with up to twelve times the systemic exposure of a normal metabolizer. That’s part of why response to PPIs varies so much between individuals, and why “it does nothing for me” and “it knocks me sideways” can both be true of the same dose in two different people.
How It Compares, Briefly
Head to head against esomeprazole (Nexium), an indirect comparison of randomized trials found dexlansoprazole 30 mg better than esomeprazole for heartburn symptom control in non-erosive reflux disease at four weeks, with no significant difference for healing or maintaining healed erosive esophagitis — and the authors were explicit that the small number of studies means this should be read cautiously [Wu et al., Alimentary Pharmacology and Therapeutics, 2013]. I compare the more common pairings in Prilosec vs Nexium, and for a genuinely different mechanism it’s worth reading about vonoprazan, which suppresses acid faster and for longer than any PPI.
Generic Dexlansoprazole and Cost
Dexilant lost exclusivity and generic dexlansoprazole is now on the market in both 30 mg and 60 mg capsules. What hasn’t happened is the price collapse people expect from a generic: cash prices still sit in the region of a few hundred dollars for 30 capsules, against a few dollars a month for generic omeprazole or pantoprazole. Insurance coverage, discount cards and direct-to-consumer pharmacies change that picture a lot, so it’s worth pricing it in your own situation rather than assuming either extreme.
That cost gap is the real decision point. If a cheap PPI is controlling your symptoms, there’s no argument for switching. If you’re getting breakthrough symptoms in the second half of the day, struggling with the before-breakfast timing rule, or have been pushed to twice-daily dosing, then paying for the longer coverage from one capsule can be a rational trade.
Coming Off It
Dexlansoprazole causes acid rebound on withdrawal like any PPI, and the longer-acting formulation doesn’t exempt it. Stopping abruptly after months of use often produces a few weeks of symptoms worse than the ones you started with, which people understandably read as proof they need the drug. Taper it instead, and have the non-drug side of your plan in place before you start — I’ve set out how to do that in getting off PPIs without acid rebound.
Conclusion
Dexlansoprazole is a well-designed PPI rather than a new kind of drug. The dual delayed-release capsule delivers a few more hours of acid control per day than lansoprazole and removes the before-breakfast timing rule, which makes it a genuinely useful option for people with second-half-of-the-day breakthrough symptoms or a schedule that defeats standard PPI dosing. For erosive esophagitis it performs at the top of its class. For silent reflux, the idea is appealing and the evidence simply isn’t there yet.
What I’d say to anyone weighing it up is that no PPI, however cleverly formulated, reduces the number of times you reflux — it only changes what the refluxate is made of. That’s why the people who do best long-term are the ones who use medication as cover while they fix the mechanics underneath. The Wipeout Diet Plan is the complete framework I built for that job: it came out of managing my own LPR, the stubborn throat-based form, but because it works on the same underlying reflux mechanisms it does just as much for GERD and everyday heartburn. Use it alongside the medication, and you give yourself a real chance of not needing the medication indefinitely. If you want a simpler starting point, the Wipeout Food Reference Guide is the essential companion — it lays out which foods and drinks are safe for reflux and LPR with their pH values, so you can cut the acid load while the drug does its part.
Frequently Asked Questions
Is Dexilant a proton pump inhibitor?
Yes. Dexilant is the brand name for dexlansoprazole, the R-enantiomer of lansoprazole, and it works by the same mechanism as every other PPI — blocking the stomach’s proton pumps. The difference is the dual delayed-release capsule, which releases the drug in two waves rather than one.
What is dexlansoprazole used for?
It’s approved for healing erosive esophagitis (60 mg daily for up to 8 weeks), maintaining that healing and relieving heartburn (30 mg daily), and treating symptomatic non-erosive GERD (30 mg daily for 4 weeks). It’s licensed for patients aged 12 and over. It is not approved for throat symptoms such as hoarseness, cough or globus.
When should I take Dexilant — morning or night?
Either. Unlike other PPIs, Dexilant can be taken without regard to food, so there’s no need to time it 30 minutes before breakfast. If your symptoms are worst overnight, an evening dose makes sense; if they’re worst during the day, take it in the morning. Consistency matters more than the exact hour.
What’s the difference between Dexilant 30 mg and 60 mg?
60 mg is the healing dose, used for up to 8 weeks in erosive esophagitis. 30 mg is the maintenance and non-erosive GERD dose. The higher dose gives longer acid suppression, but for symptom control without visible erosions the 30 mg dose is what the trials support.
What are the most common Dexilant side effects?
In trials, diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory infection (1.9%), vomiting (1.6%) and flatulence (1.6%). Longer-term, the considerations are the same as for any PPI: reduced absorption of B12, iron and magnesium, and small increases in fracture and enteric infection risk with years of use.
Is there a generic version of Dexilant?
Yes, generic dexlansoprazole is available in 30 mg and 60 mg capsules. Prices haven’t fallen to omeprazole levels though — cash prices remain substantially higher than other generic PPIs, so it’s worth checking what it actually costs under your own coverage before switching.
Does Dexilant work for silent reflux or LPR?
There’s no published randomized trial answering that — the one placebo-controlled LPR study was terminated after 11 patients. The rationale is reasonable, since longer daily acid coverage addresses the gaps that twice-daily dosing is meant to close, and a 2024 trial found once-daily dosing of a long-acting PPI as effective as twice-daily in LPR. But response rates for PPIs in LPR are modest overall, and a more expensive PPI rarely rescues a failed trial of a cheaper one.
Research & References
- [DailyMed, DEXILANT Prescribing Information, 2024] — FDA prescribing information describing the dual delayed-release formulation (plasma peaks at 1–2 hours and 4–5 hours), approved indications and doses, administration without regard to food, adverse reaction rates including diarrhea 4.8% and abdominal pain 4.0%, and up to 12-fold higher exposure in CYP2C19 poor metabolizers.
- [Olsen and Hitzeman, Clinical Medicine Insights: Therapeutics, 2009] — Review reporting that dexlansoprazole 60 mg maintained gastric pH above 4 for approximately 17 hours per day (71% of 24 hours) versus about 14 hours (60%) for lansoprazole 30 mg, healed 92–95% of erosive esophagitis at 8 weeks versus 86–92% for lansoprazole, and produced 24-hour heartburn-free days in 54.9% of non-erosive GERD patients on 30 mg versus 18.5% on placebo.
- [Ji et al., Journal of Neurogastroenterology and Motility, 2024] — Randomized controlled trial in 132 LPR patients finding no significant difference between twice-daily and once-daily dosing of a long-acting PPI in reflux symptom index response at 16 weeks (32.0% vs 37.3%), with both regimens improving symptoms and laryngeal findings.
- [Wu et al., Alimentary Pharmacology and Therapeutics, 2013] — Indirect comparison of randomized trials finding dexlansoprazole 30 mg superior to esomeprazole for heartburn symptom control in non-erosive reflux disease at 4 weeks, with no significant difference in healing or maintenance of erosive esophagitis, and noting the small number of studies as a limitation.
David Gray
12 years living with LPR · Consultant & researcher
I've lived with LPR for twelve years — the misdiagnoses, the PPI courses that did nothing, the slow work of figuring out what actually helps. Wipeout Reflux is where I translate the research into plain terms for people stuck in the same place. Every claim here is sourced to peer-reviewed work, and I consult one-to-one with LPR sufferers.